Thus, ABC294640, a selective inhibitor of SphK2, exhibited high potential to increase the sensitivity of regorafenib-resistant HCC cells to the drug (Shi et al., 2020). The gene discussed is SPHK2; the disease is hepatocellular carcinoma.